PDE4 Inhibitor Combinations for Side Effect Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Phosphodiesterase-4 (PDE4) inhibitors, while promising for treating various diseases, are limited by dose-limiting side effects such as nausea, headache, diarrhea, and respiratory tract infections, which reduce patient compliance and clinical efficacy.
Innovation Solution
Combination oral therapies comprising a PDE4 inhibitor with additional active agents like analgesics, anti-nausea agents, or proton pump inhibitors, formulated for immediate or controlled release to manage and reduce side effects, providing a single oral dosage form or separate kits for concomitant administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PDE4 inhibitor therapy is administered to treat inflammatory diseases, then therapeutic efficacy is improved, but side effects such as nausea, headache, and diarrhea increase
Solution Approach 1:
The patent introduces additional active agents as intermediaries that mediate between the PDE4 inhibitor and the patient's physiological systems. These agents (antiemetics, analgesics, antidiarrheals, etc.) act as protective intermediaries that buffer the harmful effects of the PDE4 inhibitor while allowing the therapeutic mechanism to proceed uninterrupted.
Solution Approach 2:
The patent converts the harmful side effects into beneficial outcomes by pairing the PDE4 inhibitor with agents that transform the adverse reactions. For example, nausea caused by the PDE4 inhibitor is converted into a controlled, manageable symptom through co-administration of antiemetics, thereby transforming a treatment limitation into a manageable aspect of therapy.
2Reliability
If PDE4 inhibitor dose is increased to improve clinical efficacy, then therapeutic effect is enhanced, but side effects become more severe and patient compliance decreases
Solution Approach 1:
The patent merges the PDE4 inhibitor with multiple additional active agents into a single coordinated therapy regimen. This combination approach allows the maintenance of effective PDE4 inhibitor dosing while simultaneously providing protective agents that mitigate side effects, thereby preserving patient compliance without compromising clinical efficacy.
Solution Approach 2:
The patent applies beforehand cushioning by pre-coordinating the administration of protective agents with the PDE4 inhibitor. The additional active agents are positioned to act prophylactically against anticipated side effects, cushioning the patient from adverse reactions before they fully manifest, thereby maintaining compliance even at higher effective doses.
3Object-affected harmful factors
If multiple separate medications are prescribed to manage PDE4 inhibitor side effects, then side effect management is improved, but treatment complexity and patient burden increase
Solution Approach 1:
The patent merges multiple therapeutic functions into a coordinated combination therapy where the PDE4 inhibitor and multiple additional active agents are administered together as an integrated regimen. This merging reduces the operational complexity of managing separate medications while maintaining comprehensive side effect coverage.
Solution Approach 2:
The patent creates a multi-functional treatment composition where a single therapeutic regimen simultaneously provides anti-inflammatory effects from the PDE4 inhibitor and multiple side effect management functions from the additional active agents. This universal approach allows one treatment protocol to address multiple concerns without requiring separate management systems.
Data Source
AI summary
Compositions and kits for oral administration of a phosphodiesterase-4 (PDE4) inhibitor and one or more additional active agents that reduces or eliminates a side effect associated with the PDE4 inhibitor are provided. Also provided are methods for use of these compositions and kits for treating conditions treatable with a PDE4 inhibitor therapy and for increasing patient compliance with treatment with PDE4 inhibitors.